LMT (LISCure Microbiology-based Technology) Platform Consists of the Therapeutic Screening Platform,
Microbial Optimization Platform, and Microbiome Database Platform
Therapeutic Screening Platform
- LMT-ACE TM
- LMT-MAX TM
- Metabolic Diseases
- LMT-AIR TM
- Auto-immune Diseases
- LMT-NX TM
Microbial Optimization Platform
- Novel candidate identification
- Process development
- Metabolome analysis
Microbiome Database Platform
- Gut-microbiome database
- Metagenomics & Culturomics
01. Therapeutic Screening Platform
The therapeutic screening platform for each therapeutic area is used to select drug candidates: “LMT-ACE™” for immuno-oncology, “LMT-MAX™” for metabolic diseases,
“LMT-AIR™” for autoimmune diseases, or “LMT-NX™” for neurodegenerative diseases. The platform includes a variety of in vitro and in vivo screening processes
to quantify the immune profiles of candidates and to analyze patterns and algorithms.
02. Microbial Optimization Platform
The microbial optimization platform identifies new microorganisms, establishes a microbial bank (LBMB: LISCure Biosciences Microbiome Bank), and analyzes single strains
and microorganism-derived metabolites. This platform also performs optimization so that candidate substances can enter the clinical stage
through process development tailored to strain characteristics.
03. Microbiome Database Platform
The microbiome database platform is a platform for researching microbiome and biomarkers with various tools, such as genome analysis, bioinformatics,
and machine learning, to build microbiome and metagenomic databases based on outcomes from preclinical and clinical research.
We plan to develop personalized therapeutics by analyzing the gut microbiome, individual immunity, and metabolite profiles using this platform.